Patents by Inventor Somesh Sharma
Somesh Sharma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8137708Abstract: A herbal composition comprising a therapeutically effective amount of the extract of Piper betle leaves as an active ingredient either alone, or with a pharmaceutically acceptable excipient. A process for the preparation of the herbal composition is provided. The herbal composition is adapted for the treatment of chronic myeloid leukemia (CML; chronic myelogenous leukemia) showing resistance to treatment with imatinib (Gleevec® or Glivec®).Type: GrantFiled: February 20, 2007Date of Patent: March 20, 2012Assignee: Piramal Life Sciences LimitedInventors: Kalpana Sanjay Joshi, Vilas Wagh, Somesh Sharma
-
Publication number: 20120046334Abstract: The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer.Type: ApplicationFiled: May 3, 2010Publication date: February 23, 2012Inventors: Maggie Joyce Rathos, Kalpana Sanjay Joshi, Nikhil Krishnamurthy Hebbar, Somesh Sharma
-
Publication number: 20110312528Abstract: Synergistic combinations of gemcitabine with P276-00 or P1446A and their use in the treatment of cancer are disclosed. The invention further describes novel and unique gene signatures comprising gene markers used to monitor the drug response in a subject treated with the said combinations.Type: ApplicationFiled: June 9, 2011Publication date: December 22, 2011Applicant: Piramal Life Sciences Ltd.Inventors: Periyasamy Giridharan, Debarshi Chakrabarti, Amit Khanna, Urvi Ved, Asha Almeida, Somesh Sharma, Muralidhara Padigaru, Arun Balakrishnan
-
Publication number: 20110151469Abstract: The present invention relates to a method employing Interferon Epsilon (IFNE1) as a therapeutic response, prognostic, or pharmacodynamic marker for cancer chemotherapeutic treatment involving the use of cyclin dependent kinase (CDK) inhibitors. The inventors have identified IFNE1 as a biomarker transcript that is upregulated when cancer cells are treated with CDK inhibitors. In an embodiment, the method of the invention includes measuring a level of IFNE1 mRNA or IFNE1 protein in a subject's tumor, blood or other tissue. An increase in the level of IFNE1 compared to control level can indicate that the CDK inhibitor has produced a therapeutic response or can determine whether a tumor is sensitive to a CDK inhibitor.Type: ApplicationFiled: December 9, 2010Publication date: June 23, 2011Applicant: PIRAMAL LIFE SCIENCES LIMITEDInventors: SUNITA SHANKAR, URVI VED, SOMESH SHARMA
-
Patent number: 7964631Abstract: Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-?) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-? activity, in particular inflammations.Type: GrantFiled: August 11, 2010Date of Patent: June 21, 2011Assignee: Piramal Life Sciences LimitedInventors: Bansi Lal, Somesh Sharma, Usha Ghosh, Swati Bal-Tembe, Tulsidas More, Pravin Gagare, Sunil Jadhav, Shashikant Patil, Asha Kulkarni-Almeida, Sapna Parikh, Radha Bhaskar Panicker, Anagha Damre, Ravindra Gupte
-
Publication number: 20100324026Abstract: Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R5 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-?) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-? activity, in particular inflammations.Type: ApplicationFiled: August 11, 2010Publication date: December 23, 2010Applicant: Piramal Life Sciences LimitedInventors: Bansi LAL, Somesh Sharma, Usha Ghosh, Swati Bal-Tembe, Tulsidas More, Pravin Gagare, Sunil Jadhav, Shashikant Patil, Asha Kulkarni-Almeida, Sapna Parikh, Radha Panicker, Anagha Damre, Ravindra Gupte
-
Publication number: 20100305094Abstract: Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-?) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-? activity, in particular inflammations.Type: ApplicationFiled: August 11, 2010Publication date: December 2, 2010Applicant: Piramal Life Sciences LimitedInventors: Bansi Lal, Somesh Sharma, Usha Ghosh, Swati Bal-Tembe, Tulsidas More, Asha Kulkarni-Almeida, Sapna Parikh, Radha Panicker, Anagha Damre, Ravindra Gupte
-
Publication number: 20100305057Abstract: A novel pharmaceutical combination comprising a cytotoxic antineoplastic agent selected from a the group consisting of paclitaxel, docetaxel, doxorubicin and gemcitabine or a pharmaceutically acceptable salt thereof and at least one cyclin dependent kinase (CDK) inhibitor; wherein the said combination exhibits synergistic effects when used in the treatment of cancer. The invention also relates to a method for the treatment of cancer, using a therapeutically effective amount of the said combination.Type: ApplicationFiled: May 15, 2007Publication date: December 2, 2010Applicant: PIRAMAL LIFE SCIENCES LIMITEDInventors: Maggie Rathos, Kalpana Joshi, Harshal Khanwalkar, Somesh Sharma
-
Publication number: 20100168008Abstract: The present invention relates to nucleotide and protein sequences of epiregulin and epiregulin like proteins and nucleotides and methods employing them as a drug response marker in inflammatory conditions. The invention also provides epiregulin protein for treatment of inflammatory conditions like psoriasis and rheumatoid arthritis alone or in combination with one or more anti-inflammatory compounds.Type: ApplicationFiled: November 19, 2007Publication date: July 1, 2010Applicant: PIRAMAL LIFE SCIENCES LIMITED.Inventors: Muralidhara Padigaru, Somesh Sharma, Arvind Thakkar, Anandharajan Rathina Sabapathy, Sapna Hasit Parikh, Usha Ghosh
-
Publication number: 20100152129Abstract: Synergistic combinations of gemcitabine with P276-00 or P1446A and their use in the treatment of cancer are disclosed. The invention further describes novel and unique gene signatures comprising gene markers used to monitor the drug response in a subject treated with the said combinations.Type: ApplicationFiled: December 7, 2009Publication date: June 17, 2010Inventors: Periyasamy Giridharan, Debarshi Chakrabarti, Amit Khanna, Urvi Ved, Asha Almeida, Somesh Sharma, Muralidhara Padigaru, Arun Balakrishnan
-
Publication number: 20100034746Abstract: The present invention relates to a method for evaluating a test compound for antithrombotic activity, thrombolytic activity, or a combination thereof. This method can include providing or employing a donor test animal and a recipient test animal. The donor and recipient test animals can have been pretreated with test compound. The donor test animal can be configured to provide oxygenated blood to the recipient test animal through a thrombus inducing system. This method also includes initiating transport of blood from the donor test animal to the recipient test animal through the thrombus inducing system. The method can include interrupting respiration of the recipient test animal and determining the length of time that the recipient test animal survives. In this method, a survival time longer than a predetermined threshold time indicates that the test compound has antithrombotic activity, thrombolytic activity, or a combination thereof.Type: ApplicationFiled: March 18, 2008Publication date: February 11, 2010Applicant: Piramal Life Sciences LimitedInventors: Ravindra Dattatraya Gupte, Aditi Amol Tannu, Radha Bhaskar Panicker, Somesh Sharma
-
Publication number: 20100028472Abstract: A herbal composition comprising a therapeutically effective amount of the extract of Piper betle leaves as an active ingredient either alone, or with a pharmaceutically acceptable excipient. A process for the preparation of the herbal composition is provided. The herbal composition is adapted for the treatment of chronic myeloid leukemia (CML; chronic myelogenous leukemia) showing resistance to treatment with imatinib (Gleevec® or Glivec®).Type: ApplicationFiled: February 20, 2007Publication date: February 4, 2010Applicant: PIRAMAL LIFE SCIENCES LIMITEDInventors: Kalpana Sanjay Joshi, Vilas Wagh, Somesh Sharma
-
Publication number: 20100010002Abstract: The present invention relates to the use of caffeic acid or a derivative thereof represented by the following general formula (1) wherein X is O, NH, or heterocyclyl; R may be present or absent and if present, is H, alkyl, aryl, or heterocyclyl; in all its stereoisomeric and tautomeric forms, and mixtures thereof in all ratios, and a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable polymorph or a prodrug, in the treatment of chronic myeloid leukemia (CML) which is resistant to treatment with GLEEVEC. The invention also relates to a method for reducing the proliferation of cells that are resistant to GLEEVEC by contacting the cells with a compound of general formula (1).Type: ApplicationFiled: August 20, 2007Publication date: January 14, 2010Applicant: Piramal Life Sciences LimitedInventors: Kalpana Sanjay Joshi, Meenakshi Sivakumar, Valmik Sopan Aware, Vilas Sampatrao Wagh, Amit Deshpande, Ankush Gangaram Sarde, Somesh Sharma
-
Publication number: 20090318465Abstract: The present invention relates to a method for identifying compounds that act as insulin-sensitizers. The method can include screening of test compounds in two assays of insulin sensitivity. This method can identify lead compounds for the treatment of disorders caused by insulin resistance to glucose uptake. This invention also includes methods for treating insulin resistance and related disorders.Type: ApplicationFiled: September 20, 2007Publication date: December 24, 2009Inventors: Rosalind Adaikalasamy Marita, Somesh Sharma, Jessy Anthony, Kelkar Aditya, Sujit Kaur Bhumra, Aditee Ghate, Kumar Venkata Subrahman Nemmani, Nabajyoti Deka, Ashok Kumar Gangopadhyay
-
Patent number: 7635494Abstract: This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, Sphaeranthus indicus. The said extract of Sphaeranthus indicus contains a compound, 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (7-Hydroxy-4,11(13)-eudesmadien-12,6-olide) (compound 1), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (compound 1) as an active ingredient. The invention also relates to methods of manufacture of the said compositions. The invention also relates to methods of administration of the said compositions to a subject in need of treatment for an inflammatory disorder. The invention also relates to tumor necrosis factor- (TNF-?) and interleukin (IL-1, IL-6, IL-8) inhibitory activity of the said compositions.Type: GrantFiled: March 28, 2008Date of Patent: December 22, 2009Assignee: Piramal Life Sciences LimitedInventors: Vijay Chauhan, Ashish Suthar, Dhananjay Sapre, Swati Bal-Tembe, Ashok Kumar Gangopadhyay, Asha Kulkarni-Almeida, Sapna Hasit Parikh, Ravindra Dattatraya Gupte, Nilesh Madhukar Dagia, Somesh Sharma, Shruta Sudheer Dadarkar, Mahesh Gundaji Jadhav, Aditi Amol Tannu
-
Publication number: 20090312344Abstract: The present invention relates to ?1, and/or ?1d adrenergic receptor antagonists, which can function as ?1a and/or ?1d adrenergic receptor antagonist and can be used for the treatment of a disease or disorder mediated through ?1a and/or an adrenergic receptor. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia (BPH) and the related symptoms thereof. Further, compounds disclosed herein can be used for the treatment of lower urinary tract symptoms associated with or without BPH. Also provided are processes for preparing such compounds, pharmaceutical compositions thereof, and the methods of treating BPH or related symptoms thereof.Type: ApplicationFiled: May 31, 2005Publication date: December 17, 2009Inventors: Mohammad Salman, Somesh Sharma, Gyan Chand Yadav, Gobind Singh Kapkoti, Anurag Mishra, Praful Gupta, Nitya Anand, Anita Chugh, Kamna Nanda
-
Publication number: 20090269427Abstract: This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, Sphaeranthus indicus. The said extract of Sphaeranthus indicus contains a compound, 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (7-Hydroxy-4,11(13)-eudesmadien-12,6-olide) (compound 1), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (compound 1) as an active ingredient. The invention also relates to methods of manufacture of the said compositions. The invention also relates to methods of administration of the said compositions to a subject in need of treatment for an inflammatory disorder. The invention also relates to tumor necrosis factor- (TNF-?) and interleukin (IL-1, IL-6, IL-8) inhibitory activity of the said compositions.Type: ApplicationFiled: July 9, 2009Publication date: October 29, 2009Applicant: Piramal Life Sciences LimitedInventors: Vijay CHAUHAN, Ashish SUTHAR, Dhananjay SAPRE, Swati BAL-TEMBE, Ashok Kumar GANGOPADHYAY, Asha KULKARNI-ALMEIDA, Sapna Hasit PARIKH, Ravindra Dattatraya GUPTE, Nilesh Madhukar DAGIA, Somesh SHARMA, Shruta Sudheer DADARKAR, Mahesh Gundaji JADHAV, Aditi Amol TANNU
-
Publication number: 20090241145Abstract: Embodiments of the present disclosure are directed to a system and method for receiving a request for TV programming schedule information via an interactive programming guide, obtaining the TV programming schedule information associated with a period of time, displaying one or more program icons having the TV programming schedule information associated with the interactive programming guide; adjusting at least one of a date toolbar for selecting one or more dates and a time toolbar for selecting one or more time periods of a day in response to receiving one or more commands; and displaying the one or more program icons having the TV programming schedule information associated with the interactive programming guide based at least on one of the selected one or more dates and the selected one or more time periods of the day.Type: ApplicationFiled: March 24, 2008Publication date: September 24, 2009Applicant: VERIZON DATA SERVICES LLCInventor: SOMESH SHARMA
-
Publication number: 20080254157Abstract: This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, Sphaeranthus indicus. The said extract of Sphaeranthus indicus contains a compound, 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (7-Hydroxy-4,11(13)-eudesmadien-12,6-olide) (compound 1), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (compound 1) as an active ingredient. The invention also relates to methods of manufacture of the said compositions. The invention also relates to methods of administration of the said compositions to a subject in need of treatment for an inflammatory disorder. The invention also relates to tumor necrosis factor- (TNF-?) and interleukin (IL-1, IL-6, IL-8) inhibitory activity of the said compositions.Type: ApplicationFiled: March 28, 2008Publication date: October 16, 2008Applicant: PIRAMAL LIFE SCIENCES LIMITEDInventors: Vijay Chauhan, Ashish Suthar, Dhananjay Sapre, Swati Bal-Tembe, Ashok Kumar Gangopadhyay, Asha Kulkarni-Almeida, Sapna Hasit Parikh, Ravindra Dattatraya Gupte, Nilesh Madhukar Dagia, Somesh Sharma, Shruta Sudheer Dadarkar, Mahesh Gundaji Jadhav, Aditi Amol Tannu
-
Publication number: 20070299050Abstract: Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-?) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-? activity, in particular inflammations.Type: ApplicationFiled: November 8, 2005Publication date: December 27, 2007Applicant: Nicholas Piramal India Limited.Inventors: Bansi Lal, Somesh Sharma, Usha Ghosh, Swati Bal-Tembe, Tulsidas More, Pravin Gagare, Sunil Jadhav, Shashikant Patil, Asha Kulkarni-Almeida, Sapna Parikh, Radha Panicker, Anagha Damre, Ravindra Gupte